Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find University Hospitals Doctors
Michael Konstan, MD

Michael Konstan, MD

Office Locations

UH Rainbow Babies & Children's Hospital (0 mi.)

11100 Euclid Ave
Ste 170
Cleveland, OH 44106

UH Rainbow Babies & Children's Hospital (0 mi.)

11100 Euclid Ave
Ste 604
Cleveland, OH 44106

UH Fairlawn Health Center (25 mi.)

3800 Embassy Pkwy
Ste 250
Fairlawn, OH 44333

Biography: Michael Konstan, MD


  • Cystic Fibrosis


  • Vice Chairman, Clinical Research, UH Rainbow Babies and Children's Hospital
  • Professor, CWRU School of Medicine
  • Austin Ricci Chair in Pediatric Pulmonary Care and Research, UH Rainbow Babies & Children's Hospital

Certifications & Memberships

  • Pediatric Pulmonology - American Board of Pediatrics
  • Pediatrics - American Board of Pediatrics


Fellowship | Pediatric Pulmonology
Pediatric Pulmonology - University Hospitals Of Cleveland (1985 - 1988)

Residency | Pediatrics
Pediatrics - Kaleida Health System (Women And Children's Hosp Of Buffalo) (1983 - 1985)

Internship | Pediatrics
Pediatrics - Kaleida Health System (Women And Children's Hosp Of Buffalo) (1982 - 1983)

Medical Education
Case Western Reserve University School Of Medicine (1982)

Case Western Reserve University (1978)


Michael W. Konstan, MD, is board certified in pediatrics and pediatric pulmonology. His special interest is cystic fibrosis.

Dr. Konstan is a graduate of Case Western Reserve University School of Medicine. He completed his residency in pediatrics at Children's Hospital of Buffalo in Buffalo, N.Y., and a fellowship in pediatric pulmonology at UH Rainbow Babies and Children’s Hospital and Case Western Reserve University School of Medicine. He was named to the University Hospitals medical staff in 1988.

Dr. Konstan has served on numerous advisory boards and grant review committees for the Cystic Fibrosis Foundation, the U.S. Food and Drug Administration (FDA), the National Institutes of Health, and many pharmaceutical and biotechnology companies. He was a founding member of the Cystic Fibrosis Foundation Therapeutic Development Network, and he currently serves on the Cystic Fibrosis Foundation Research Executive Committee. Locally, he serves on the Board of Directors of the foundation’s Northern Ohio Chapter.

An internationally renowned physician-scientist specializing in cystic fibrosis, Dr. Konstan’s research has been funded by the Cystic Fibrosis Foundation, the FDA, the National Institutes of Health, and numerous pharmaceutical and biotechnology companies focused on developing therapeutics for the treatment and cure of cystic fibrosis. He has been the lead investigator on several national and international clinical trials that have led to the approval of new therapeutics for cystic fibrosis.

Dr. Konstan has published more than 150 peer-reviewed papers in leading medical journals reporting basic and clinical research related to cystic fibrosis, as well as more than a dozen textbook chapters. He has presented more than 200 abstracts at scientific meetings and conferences, both nationally and internationally. He also is a reviewer for numerous peer-reviewed journals, including the Journal of the American Medical Association, Lancet, and the New England Journal of Medicine.

In 2013, Dr. Konstan was awarded the Case Western Reserve Medal for Excellence in Health Science Innovation by the School of Medicine. He is a member of the American Pediatric Society, American Academy of Pediatrics, American Thoracic Society, and Society for Pediatric Research.

Research & Publications

Research Interests

Cystic fibrosis

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Michael Konstan disclosed the following Outside Relationships with Industry:

  • - Aradigm - Consulting
  • - Axcan-Pharma - Consulting
  • - Eli Lilly - Consulting
  • - Genentech - Consulting
  • - Novartis - Consulting
  • - Vertex - Consulting